Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) has provided an update.
Qyuns Therapeutics Co., Ltd. has announced a board meeting scheduled for March 28, 2025, to discuss and approve the annual results for the year ending December 31, 2024. The meeting will also consider the recommendation of a final dividend and address other business matters, potentially impacting the company’s financial strategies and shareholder returns.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on developing therapeutic solutions and is listed on the Hong Kong Stock Exchange under the stock code 2509.
YTD Price Performance: 49.05%
Average Trading Volume: 70,129
Technical Sentiment Consensus Rating: Strong Buy
For an in-depth examination of 2509 stock, go to TipRanks’ Stock Analysis page.